All In Biotech

Drug Trial Radar · NCT07904546

ADBest TREAT Registry

ADBest-TREAT: A Registry for Patients With Atopic Dermatitis Receiving Systemic, Local, or UV Therapy

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

5,000

Planned (sponsor's estimate)

Start

Jan 1, 2023

Primary completion

Dec 31, 2032

Study completion Dec 31, 2032

Sponsor

Lead sponsor
Universitätsklinikum Hamburg-EppendorfAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 29, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Atopic dermatitis is a chronic inflammatory skin disease associated with intense pruritus, recurrent eczematous lesions, sleep disturbance, and reduced quality of life. The disease may be influenced by genetic factors, environmental triggers, epidermal barrier dysfunction, and immune dysregulation. Patients may experience flares triggered by allergens, infections, dry skin, stress, irritants, or other environmental factors. Atopic dermatitis can also be associated with secondary bacterial or viral skin infections and a substantial burden on daily activities, work productivity, sleep, and psychosocial well-being.TREAT is the German national treatment registry for patients with atopic dermatitis. The registry collects real-world data from routine dermatological care to assess disease course, treatment patterns, disease burden, patient-relevant treatment benefits, and quality of life. Data are collected electronically using physician-completed eCRFs and patient-completed questionnaires at inclusion and follow-up visits. The registry aims to improve understanding of atopic dermatitis real-world care and outcomes in daily clinical practice.

Conditions

  • Atopic Dermatitis

Interventions

  • AbrocitinibDrug

    Oral JAK1 inhibitor administered fot the treatment of atopic dermatitis.

  • BaricitinibDrug

    Oral JAK1 inhibitor administered for the treatment of atopic dermatitis.

  • UpadacitinibDrug

    Oral JAK1 inhibitor administered for the treatment of atopic dermatitis.

  • DupilumabBiological

    Monaclonal antibody targeting IL4 and IL-13 receptors fot the treatment of moderate to severe atopic dermatitis.

  • LebrikizumabBiological

    Monaclonal antibody targeting IL-13 receptors fot the treatment of moderate to severe atopic dermatitis.

  • NemolizumabBiological

    Monoclonal antibody targeting IL31 receptor alpha to inhibit pruritus and inflammation in atopic dermatitis.

  • TralokinumabBiological

    Monoclonal antibody neutralizing IL13 specifically for the treatment of atopic dermatitis.

  • Conventional Systemic TherapyOther

    Conventional systemic treatments including traditional immunosuppressants or corticosteroids administrated for moderate to severe atopic dermatitis.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Eczema Area and Severity Index(EASI) scoreTime frame: At registry inclusion (week 0),at weeks 16,28, and 52 ,and every 24 weeks thereafter through 60 months.
  2. Dermatology Life Quality Index (DLQI) scoreTime frame: At registry inclusion (week 0),at weeks 16,28, and 52 ,and every 24 weeks thereafter through 60 months;an additional visit during weeks 0-4 may occur optionally.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute for Health Services Research in Dermatology and Nursing, IVDP; University Medical Center Hamburg-Eppendorf,UKE

    Hamburg, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.